Treatment of cancer using tlr9 agonist with checkpoint inhibitors
AssigneeIdera Pharmaceuticals, Inc.
InventorsDaqing Wang, Wayne Jiang, Sudhir Agrawal
Life of this patent
Estimating the term…
Abstract
The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more TLR9 agonists and one or more checkpoint inhibitors. Preferably, the one or more TLR9 agonists are administered to the patient via intratumoral (i.t.) administration.
Claims20
A method for treating cancer in a patient, the method comprising the co-administration of a compound comprising the sequence 5-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5, wherein G1 is 2′-deoxy-7-deazaguanosine and X is a glycerol linker and one or more checkpoint inhibitors, wherein the compound is administered intratumorally.
A method for treating cancer in a patient, the method comprising the co-administration a compound comprising the sequence 5-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5, wherein G1 is 2′-deoxy-7-deazaguanosine and X is a glycerol linker, a checkpoint inhibitor of IDO1, and one or more additional checkpoint inhibitors, wherein the compound is administered intratumorally.
Dependencies are inferred from the claim text.